Practical Consensus Guidelines on the Use of Cetuximab in Head and Neck Squamous Cell Carcinoma (HNSCC).

ression or alterations are seen in almost all patients with HNSCC. 7 Its adverse independent prognostic implication is established (reduced overall survival [OS]) in HNSCC. 8 As far back as in 2006, value of treating HNSCC patients with CTX (anti-EGFR monoclonal antibody) was established with a highly significant improvement in 5-year OS. 9 10 11 12 13 14 Subsequently, a multitude of clinical studies consolidated its role in various HNSCC scenarios—with chemoradiotherapy (CRT), radiotherapy (RT), organ preservation, and combination systemic therapy. 15 16 17 18 19 20 21 22 23 24 25 This includes impressive data from India as well. 26 27 A score (two decades) later, CTX continues to play a vital role in the management of HNSCC. 28 This is because it has several modes of action.

also in 132,142 other papers